Market capitalization | $319.55m |
Enterprise Value | $269.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.71 |
P/S ratio (TTM) P/S ratio | 6.76 |
P/B ratio (TTM) P/B ratio | 4.89 |
Revenue growth (TTM) Revenue growth | 34.38% |
Revenue (TTM) Revenue | $47.26m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a CVRx Inc forecast:
7 Analysts have issued a CVRx Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 47 47 |
34%
34%
|
|
Gross Profit | 39 39 |
37%
37%
|
|
EBITDA | -58 -58 |
31%
31%
|
EBIT (Operating Income) EBIT | -59 -59 |
31%
31%
|
Net Profit | -58 -58 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | Kevin Hykes |
Employees | 200 |
Founded | 2001 |
Website | www.cvrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.